Literature DB >> 21750584

Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO).

Charles A Herzog1, Richard W Asinger, Alan K Berger, David M Charytan, Javier Díez, Robert G Hart, Kai-Uwe Eckardt, Bertram L Kasiske, Peter A McCullough, Rod S Passman, Stephanie S DeLoach, Patrick H Pun, Eberhard Ritz.   

Abstract

Cardiovascular morbidity and mortality in patients with chronic kidney disease (CKD) is high, and the presence of CKD worsens outcomes of cardiovascular disease (CVD). CKD is associated with specific risk factors. Emerging evidence indicates that the pathology and manifestation of CVD differ in the presence of CKD. During a clinical update conference convened by the Kidney Disease: Improving Global Outcomes (KDIGO), an international group of experts defined the current state of knowledge and the implications for patient care in important topic areas, including coronary artery disease and myocardial infarction, congestive heart failure, cerebrovascular disease, atrial fibrillation, peripheral arterial disease, and sudden cardiac death. Although optimal strategies for prevention, diagnosis, and management of these complications likely should be modified in the presence of CKD, the evidence base for decision making is limited. Trials targeting CVD in patients with CKD have a large potential to improve outcomes.

Entities:  

Mesh:

Year:  2011        PMID: 21750584     DOI: 10.1038/ki.2011.223

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  252 in total

Review 1.  Diagnosis and Management of Heart Failure in Long-Term Dialysis Patients.

Authors:  Ashraf S Abdo
Journal:  Curr Heart Fail Rep       Date:  2017-10

2.  Initiation of dialysis: Trigger or cause of cardiovascular events?

Authors:  Wojciech Zareba
Journal:  Kidney Int       Date:  2015-11       Impact factor: 10.612

3.  Cardiovascular risk assessment with regadenoson SPECT MPI in patients with end-stage renal disease is safe, effective, and well tolerated: Does it matter?

Authors:  Erica O Miller; Ronald G Schwartz
Journal:  J Nucl Cardiol       Date:  2015-12-01       Impact factor: 5.952

Review 4.  PCSK9 in chronic kidney disease.

Authors:  P Pavlakou; E Liberopoulos; E Dounousi; M Elisaf
Journal:  Int Urol Nephrol       Date:  2017-01-13       Impact factor: 2.370

5.  Mild renal dysfunction and long-term adverse outcomes in women with chest pain: results from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE).

Authors:  Rajesh Mohandas; Mark Segal; Titte R Srinivas; B Delia Johnson; Xuerong Wen; Eileen M Handberg; John W Petersen; George Sopko; C Noel Bairey Merz; Carl J Pepine
Journal:  Am Heart J       Date:  2015-01-06       Impact factor: 4.749

6.  Standards of clinical practice for renal pharmacists.

Authors:  Colette B Raymond; Lori D Wazny; Amy R Sood
Journal:  Can J Hosp Pharm       Date:  2013-11

7.  Physical Activity and Cardiovascular Risk among Kidney Transplant Patients.

Authors:  Augustine W Kang; Carol Ewing Garber; Charles B Eaton; Patricia M Risica; Andrew G Bostom
Journal:  Med Sci Sports Exerc       Date:  2019-06       Impact factor: 5.411

8.  Antihypertensive Medication Use in Older Patients Transitioning from Chronic Kidney Disease to End-Stage Renal Disease on Dialysis.

Authors:  Tara I Chang; Yuanchao Zheng; Maria E Montez-Rath; Wolfgang C Winkelmayer
Journal:  Clin J Am Soc Nephrol       Date:  2016-06-27       Impact factor: 8.237

Review 9.  Calcium as a cardiovascular toxin in CKD-MBD.

Authors:  Sharon M Moe
Journal:  Bone       Date:  2016-08-27       Impact factor: 4.398

Review 10.  Kidney-brain crosstalk in the acute and chronic setting.

Authors:  Renhua Lu; Matthew C Kiernan; Anne Murray; Mitchell H Rosner; Claudio Ronco
Journal:  Nat Rev Nephrol       Date:  2015-08-18       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.